



Corporate Fact Sheet

About Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals, Inc. is a privately held biopharmaceutical company dedicated to developing and commercializing high-impact therapeutics that address critical unmet needs, primarily in the treatment of neurodegenerative diseases. Neuraltus has three clinical-stage programs in its development pipeline, including potential treatments for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Parkinson's disease and dyskinesias associated with the treatment of Parkinson's disease, Alzheimer's disease, and Multiple Sclerosis, as well as lysosomal storage disorders such as Fabry's disease and Gaucher's disease.

Clinical Pipeline

Neuraltus' programs focus on novel drug molecules with promising mechanisms of action representing first-in-class approaches to treating the Company's target disease indications.

Clinical Pipeline

	Preclinical	Phase 1	Phase 2	Phase 3
NP001	<i>Macrophage regulation</i>			
NP002	<i>Nicotinic receptor agonism</i>			
NP003	<i>Undisclosed</i>			

Financing

Neuraltus began operations in 2009 and closed a \$17M Series A financing in March of that year with leading venture groups Latterell Venture Partners, VantagePoint Venture Partners and Adams Street Partners.

Milestones

- 2H2010: Report data from Phase 1 clinical study of NP001 for ALS
- 2H2010: Report data from Phase 1/2 clinical study of NP002 for the reduction of L-dopa-induced dyskinesias
- 1Q2011: Initiate Phase 2 clinical study of NP001 for ALS
- 3Q2011: Initiate Phase 1/2 clinical testing of NP003 in lysosomal storage disorder

About NP001

NP001, a novel, proprietary approach that regulates macrophage activation, targets diseases including ALS, Parkinson's disease, Alzheimer's disease and Multiple Sclerosis. NP001 is designed to transform select immune cells (macrophages) from a neurotoxic state to a neuroprotective state, normalizing the cellular environment of critical nerve cells.

A recent Phase 1, single ascending dose study in 32 individuals with ALS showed NP001 was safe and well-tolerated at four different dose levels. Importantly, following a single dose, there was a dose-dependent, statistically significant improvement in blood levels of the biomarker thought to be involved in ALS disease progression; this is a first in ALS. The results of the study are encouraging, providing the first clinical evidence that a therapeutic agent may be able to modify the activation state of macrophages in patients with ALS.

About NP002

NP002, a small molecule, nicotinic receptor agonist, is designed to reduce dyskinesias (muscle movement disorders) that are a primary side effect of L-dopa treatment of Parkinson's disease. Of the 500,000 - 1.5 million Parkinson's patients in the United States, more than 50% experience L-dopa-induced dyskinesias (LIDs). In Phase 1/2 studies NP002 administered concurrently with L-dopa treatment was found to be generally safe and well-tolerated in Parkinson's patients with LIDs. In addition, NP002 was not associated with any impulsivity or withdrawal issues when compared to placebo. Although the trial was not powered as an efficacy study, clinically relevant trends and, in two cases, statistical superiority of NP002 over placebo were observed in a variety of physician- and patient-rated PD efficacy outcome measures relating to dyskinesias.

About NP003

NP003 is an orally bioavailable, small molecule designed to treat lysosomal storage disorders such as Fabry's disease and Gaucher's disease. NP003 works by limiting the ability of harmful lipids to collect in the cells of lysosomal storage disorder patients. NP003 is expected to be synergistic with current enzyme replacement therapies. In addition, because it crosses the blood-brain barrier, NP003 is expected to provide central nervous system protection from abnormal lipid accumulation. NP003 may also inhibit glycolipid-induced aggregation in the brain of α -synuclein protein, believed to be a primary cause of Parkinson's disease.

Neuraltus Leadership

Andrew Gengos

President, Chief Executive Officer and Director

Annette Bianchi

*Neuraltus Director
VantagePoint Venture Partners*

Terry Gould

*Neuraltus Director
Adams Street Partners*

Jim Woody, M.D., Ph.D.

*Neuraltus Director
Latterell Venture Partners*

Founders

Michael McGrath, M.D., Ph.D.

Professor of Laboratory Medicine, University of California, San Francisco

Edgar Engleman, M.D.

Professor of Medicine and Pathology, Stanford University School of Medicine

Ari Azhir, Ph.D.

Neuraltus Pharmaceuticals

2483 E. Bayshore Road
Suite 212
Palo Alto, CA 94303

(650) 424-1600

www.neuraltus.com

Updated: Second Quarter 2011